IL302386A - Methods for reducing tau in humans - Google Patents

Methods for reducing tau in humans

Info

Publication number
IL302386A
IL302386A IL302386A IL30238623A IL302386A IL 302386 A IL302386 A IL 302386A IL 302386 A IL302386 A IL 302386A IL 30238623 A IL30238623 A IL 30238623A IL 302386 A IL302386 A IL 302386A
Authority
IL
Israel
Prior art keywords
serum
tau
administration
csf
days
Prior art date
Application number
IL302386A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL302386A publication Critical patent/IL302386A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL302386A 2020-10-26 2021-10-25 Methods for reducing tau in humans IL302386A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (1)

Publication Number Publication Date
IL302386A true IL302386A (en) 2023-06-01

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302386A IL302386A (en) 2020-10-26 2021-10-25 Methods for reducing tau in humans

Country Status (11)

Country Link
US (1) US20220127345A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232155A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023546504A (cg-RX-API-DMAC7.html)
KR (1) KR20230093499A (cg-RX-API-DMAC7.html)
CN (1) CN116916955A (cg-RX-API-DMAC7.html)
AU (1) AU2021367878A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199806A1 (cg-RX-API-DMAC7.html)
IL (1) IL302386A (cg-RX-API-DMAC7.html)
MX (1) MX2023004831A (cg-RX-API-DMAC7.html)
TW (1) TW202233666A (cg-RX-API-DMAC7.html)
WO (1) WO2022090158A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード-ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3551655A2 (en) * 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
WO2019171258A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
US20230075314A1 (en) * 2019-04-29 2023-03-09 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
JP2023546503A (ja) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ.ベー. 抗タウ抗体の安全な投与方法

Also Published As

Publication number Publication date
EP4232155A1 (en) 2023-08-30
AU2021367878A1 (en) 2023-06-22
TW202233666A (zh) 2022-09-01
US20220127345A1 (en) 2022-04-28
WO2022090158A1 (en) 2022-05-05
JP2023546504A (ja) 2023-11-02
KR20230093499A (ko) 2023-06-27
CA3199806A1 (en) 2022-05-05
MX2023004831A (es) 2023-07-12
CN116916955A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
IL272615A (en) Human antibodies that detect alpha-synuclein, preparations containing them and their uses
IL272321B1 (en) Methods and compositions for treating amyloid deposition diseases
CA3143811A1 (en) Anti-tau antibody and use of same
IL323583A (en) Methods for treating and preventing Alzheimer's disease
KR20020089359A (ko) Aβ 펩티드를 격리시키는 인간화 항체
EP3135689A1 (en) Phosphospecific antibodies recognising tau
IL272361B1 (en) Antibodies that bind active alpha-synuclein
IL300059A (en) Anti-Abata antibodies
IL302383A (en) A method for the safe administration of anti-tau antibodies
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
IL318087A (en) Antibody against human TRL7
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
JP2024532438A (ja) 抗Aβプロトフィブリル抗体の皮下製剤及びその使用方法
WO2014160133A2 (en) Anti-(+) --methamphetamine monoclonal antibodies
IL322281A (en) Methods for treating neurological disorders with anti-Abeta antibodies
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (en) Methods of reducing tau in human subjects
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
IL296579A (en) Antibody against ccl24 for use in a treatment method
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку